HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M

This publication has 9 references indexed in Scilit:

• Genotypic and Phenotypic Cross-Resistance Patterns to Lopinavir and Amprenavir in Protease Inhibitor-Experienced Patients with HIV Viremia
  AIDS Research and Human Retroviruses, 2002
• Overcoming drug resistance in HIV‐1 chemotherapy: The binding thermodynamics of Amprenavir and TMC‐126 to wild‐type and drug‐resistant mutants of the HIV‐1 protease
  Protein Science, 2002
• Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors
  Antimicrobial Agents and Chemotherapy, 2002
• HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients
  AIDS, 2002
• A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
  Antimicrobial Agents and Chemotherapy, 2000
• Combination Therapy with Amprenavir, Abacavir, and Efavirenz in Human Immunodeficiency Virus (HIV)-Infected Patients Failing a Protease-Inhibitor Regimen: Pharmacokinetic Drug Interactions and Antiviral Activity
  Clinical Infectious Diseases, 2000
• Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
  AIDS, 1999
• In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
  Journal of Virology, 1995
• Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
  Journal of the American Chemical Society, 1995